U.S. Radiation Oncology Devices Market

Market Outlook

By 2035, the U.S. Radiation Oncology Devices Market is expected to reach approximately USD 8.44 billion, expanding at a CAGR of 8.83% during the forecast period 2026–2035. The market was valued at approximately USD 3.62 billion in 2025, following expansion from around USD 2.60 billion in 2021, USD 2.82 billion in 2022, USD 3.07 billion in 2023, and USD 3.34 billion in 2024. Values in this report are expressed in USD billions.

Radiation oncology remains one of the most technology-intensive areas of U.S. cancer care. In 2025, an estimated 2.04 million new cancer cases were expected to be diagnosed nationally, creating sustained clinical demand for radiation treatment across breast, prostate, lung, brain, head and neck, gynecologic and other malignancies. Radiation therapy is used during the treatment pathway of more than half of cancer patients, making radiation treatment infrastructure strategically important to hospitals, academic cancer centers and community oncology networks.

The equipment market is progressing beyond conventional linear accelerator replacement toward a broader precision-radiation ecosystem integrating high-quality on-board imaging, online adaptive therapy, artificial intelligence-assisted planning, surface guidance, stereotactic delivery, motion management, proton therapy and increasingly automated quality assurance. The economic objective is also changing. Hospitals are no longer evaluating radiation platforms solely by maximum beam capability or capital cost; purchasing committees increasingly evaluate throughput, treatment-room utilization, staffing requirements, number of fractions, imaging workflow, adaptive planning time, uptime, service economics and reimbursement sustainability.

The historical period from 2021 to 2024 was characterized by deferred equipment replacement being released after the pandemic, recovery of oncology procedure volumes, expansion of stereotactic body radiation therapy, growing adoption of image-guided treatment and renewed capital investment by comprehensive cancer centers. The market strengthened further in 2025 as U.S. institutions invested in advanced CT-guided and adaptive radiotherapy platforms, modernized aging accelerator fleets and expanded proton and specialty radiation capacity.

The next investment cycle will be driven less by simply adding treatment rooms and more by increasing clinical capability within each room. Systems capable of supporting conventional fractionation, hypofractionation, SBRT, SRS, adaptive radiotherapy and complex image-guided treatment from a common platform can generate stronger economic justification because they expand case mix while protecting capital utilization.

Introduction

According to the U.S. Radiation Oncology Devices Market Report, demand is shaped by the interaction of cancer incidence, aging demographics, precision-treatment requirements, hospital capital budgets, workforce availability, reimbursement policy and the need to bring advanced cancer treatment closer to patients.

The United States has one of the world’s most sophisticated radiation oncology infrastructures, supported by NCI-designated cancer centers, large academic institutions, regional oncology systems, hospital outpatient departments, physician-owned centers, proton therapy facilities and community-based oncology networks. However, infrastructure remains unevenly distributed. In 2025, approximately 68.5% of U.S. counties, representing around 50.8 million Americans, lacked a radiation oncology practice site. This creates a market in which high-end technological sophistication and significant geographic access gaps exist simultaneously.

The resulting purchasing environment varies substantially by facility type. Major academic cancer centers are increasingly focused on adaptive radiation therapy, MR or advanced CT guidance, proton treatment, biology-guided radiotherapy and automation. Large integrated delivery networks are prioritizing fleet standardization, interoperable treatment planning and enterprise oncology management. Community radiation centers place greater weight on reliability, staffing efficiency, installation requirements and total cost of ownership.

Radiation oncology is also unusually sensitive to reimbursement policy because equipment requires high upfront capital investment while revenue is generated across repeated fractions and related planning, imaging and technical services. Medicare payment changes therefore influence capital replacement cycles, particularly among freestanding facilities. Radiation therapy reimbursement has experienced significant cumulative pressure over the past decade, and 2026 coding changes created additional financial stress for a number of community and freestanding practices.

This pressure will influence device strategy rather than eliminate technology demand. Capital is increasingly likely to concentrate around platforms that improve utilization per treatment room, reduce manual planning steps, shorten image acquisition or patient setup, automate contouring and QA, enable hypofractionated treatment and support differentiated clinical programs such as adaptive therapy or radiosurgery.

For manufacturers, the addressable opportunity therefore extends beyond selling accelerators. The strongest competitive models increasingly connect treatment delivery with imaging, simulation, treatment planning, oncology information systems, motion management, patient positioning, dosimetry, QA, service contracts and clinical implementation support.

Key Market Drivers: What’s Fueling the U.S. Radiation Oncology Devices Market Boom?

The first structural driver is the scale of the U.S. cancer population. Approximately 2,041,910 new cancer cases and 618,120 cancer deaths were estimated for 2025. Breast, prostate, lung and bronchus, colorectal and other high-incidence cancers collectively generate a large pool of patients who may require curative, adjuvant or palliative radiation treatment. Radiation oncology device demand is therefore tied not simply to cancer prevalence but to the increasing number of patients living long enough to receive multimodal treatment.

A second major driver is the transition toward hypofractionation and high-precision radiation. Traditional radiation treatment frequently involved long courses delivered over several weeks. Modern clinical protocols increasingly support fewer fractions for selected breast, prostate, lung, metastatic and other indications. This changes device economics. Although fewer fractions can reduce treatment visits per patient, advanced technologies such as SBRT, SRS, IGRT, motion management and adaptive planning require greater precision and typically increase the technological intensity of individual fractions. Systems capable of treating more patients in fewer visits can also improve access and room capacity.

A third driver is the replacement cycle of installed linear accelerators. Radiation treatment systems operate for many years, creating a recurring modernization requirement across U.S. hospitals and cancer centers. Replacement decisions increasingly involve more than basic accelerator age. Providers are upgrading because newer platforms provide higher-quality CBCT, improved workflow automation, more sophisticated multileaf collimation, integrated surface guidance, advanced motion management and compatibility with online adaptation.

A fourth driver is the growth of adaptive radiotherapy. Anatomical relationships between tumors and organs at risk can change during treatment because of tumor response, weight change, bladder and bowel filling, respiration and other factors. Conventional treatment planning historically relied heavily on anatomy captured during simulation. Adaptive systems can use images acquired near treatment time to revise the plan around current anatomy. This capability is attracting investment because it increases personalization while creating a differentiated clinical offering.

A fifth driver is the development of proton and particle therapy infrastructure. The United States had approximately 50 operating proton therapy centers by 2026, with additional centers and expansions under development. Proton technology remains concentrated because of high capital requirements, but development of single-room systems and more compact configurations has broadened the potential addressable provider base. Proton therapy is particularly relevant to pediatric oncology, selected CNS tumors, head and neck cancer, prostate cancer and cases where reducing integral dose to surrounding tissue has high clinical value.

The sixth driver is cancer-center competition. Radiation oncology programs influence referrals, surgical and medical oncology volumes, imaging utilization and the reputation of hospital cancer service lines. Major health systems consequently use advanced radiation technology as part of broader cancer-center positioning. Investments are often evaluated against referral retention and enterprise oncology strategy rather than radiation department revenue alone.

The seventh driver is workforce pressure. Radiation oncologists, medical physicists, dosimetrists and radiation therapists remain essential to safe treatment delivery, and staffing constraints are especially difficult for rural and smaller centers. Technology that automates contouring, planning, image registration, patient positioning, QA preparation and repetitive workflow steps can therefore carry measurable labor value. Equipment vendors increasingly compete on the number of staff interactions required per treatment episode.

Reimbursement represents both a driver and a constraint. Medicare radiation oncology payment has faced long-term downward pressure, while 2026 changes created significant disruption for some facilities. The consequence is greater scrutiny of capital expenditure. Health systems are favoring platforms with measurable effects on throughput, fraction economics, labor requirements, service costs and equipment uptime.

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in radiation oncology is shifting from beam generation toward intelligent treatment ecosystems. Accuracy remains fundamental, but hospitals increasingly expect equipment to combine imaging, planning, treatment delivery, motion management, automation and operational analytics.

One major innovation area is high-quality imaging directly on the treatment system. Modern cone-beam CT technology can provide substantially better soft-tissue visualization and faster acquisition than earlier generations. Advanced systems can generate images suitable not only for localization but also for dose calculation and adaptive replanning. Varian’s HyperSight technology, for example, demonstrated the ability to acquire certain CBCT images in approximately six seconds compared with substantially longer conventional acquisitions. Faster imaging can reduce motion artifacts, shorten table time and improve patient tolerance.

CT-guided adaptive radiotherapy is entering an important U.S. commercialization period. Elekta received U.S. FDA clearance for its Evo CT-Linac in January 2026, while Varian continues to expand its Ethos adaptive ecosystem. These platforms are designed around higher-quality daily anatomy visualization and automated or semi-automated replanning. Their commercial significance extends beyond clinical precision: adaptive treatment can create a differentiated radiation service line and increase the strategic value of oncology software.

Artificial intelligence is increasingly embedded throughout the workflow. AI-supported segmentation can reduce manual contouring, automated planning can create clinically acceptable treatment alternatives faster, and decision-support tools can prioritize cases or identify anatomical changes requiring intervention. The competitive advantage will increasingly belong to manufacturers that make AI operationally invisible rather than requiring separate workflows.

Motion management is another important innovation domain. Lung, liver, pancreas and other thoracic or abdominal tumors can move significantly during respiration. Surface-guided radiation therapy, internal fiducial tracking, respiratory gating and real-time beam control are becoming increasingly important as stereotactic doses rise. Better motion management supports smaller margins around tumors, potentially reducing dose to healthy tissue.

Biology-guided radiotherapy represents a more disruptive concept. RefleXion’s platform combines PET-related biological signals with external-beam radiation delivery, creating the possibility of using biological information from a tumor to influence targeting during treatment. FDA clearance of the next-generation RefleXion X2 platform in late 2025 and its U.S. launch activity in 2026 demonstrate continued investment in treatment architectures beyond conventional image-guided linacs.

Particle therapy is also evolving. Single-room proton systems are reducing some of the infrastructure complexity historically associated with multi-room proton centers. At the same time, the United States is preparing for the emergence of carbon-ion therapy, with development activity associated with Mayo Clinic in Florida representing an important strategic milestone for U.S. particle therapy.

Radiation oncology innovation is therefore moving toward a future in which treatment rooms operate as connected precision platforms. Winning technologies will be those that improve dose delivery while simultaneously reducing friction in simulation, planning, setup, imaging, adaptation, QA and documentation.

Segmentation Insights

The U.S. Radiation Oncology Devices Market is segmented on the basis of product category, application, end user, technology type and region.

By Product Category

External Beam Radiation Therapy Systems

External beam radiation therapy systems represent the largest product category in the U.S. market. The segment includes medical linear accelerators, stereotactic radiosurgery systems, robotic radiosurgery platforms and helical treatment delivery systems. LINAC platforms remain the backbone of U.S. radiation oncology because they can support treatment across a broad cancer case mix.

Growth is increasingly concentrated in premium replacement systems offering integrated imaging, automated positioning, high-dose-rate delivery, motion management and adaptive functionality. Providers are seeking versatile systems that can handle routine IMRT and VMAT while also supporting SBRT, SRS and complex retreatment.

Brachytherapy Devices

Brachytherapy devices include high-dose-rate afterloaders, applicators, needles, catheters, low-dose-rate seed implantation technologies, electronic brachytherapy systems and related source delivery devices. The segment remains clinically important in prostate, cervical, uterine, breast, skin and selected intracranial treatments.

HDR brachytherapy maintains a durable role in gynecologic oncology, while permanent seed technologies retain selected prostate indications. Specialized intracranial brachytherapy products, including surgically placed radiation implants, illustrate how the category is evolving beyond traditional treatment pathways.

Particle Therapy Systems

Particle therapy includes proton beam systems and emerging heavy-ion platforms. Proton treatment is one of the highest-capital product categories in radiation oncology but represents an important premium growth segment.

Approximately 50 proton centers were operating nationally by 2026, with additional facilities planned or under development. The U.S. market is moving toward greater use of single-room installations alongside established multi-room centers, reducing the infrastructure barrier for selected academic and regional cancer programs.

Simulation and Imaging Systems

Radiation oncology simulation and imaging equipment includes dedicated CT simulators, MRI-based simulation systems, on-board cone-beam CT, treatment-room imaging, image registration technologies and related guidance hardware.

This category is gaining strategic importance because radiation accuracy depends on accurate anatomical definition before and during treatment. As adaptive therapy expands, imaging is becoming part of the treatment-delivery process rather than a separate pre-treatment step.

Radiotherapy Accessories, QA and Positioning Devices

This segment includes patient immobilization systems, positioning devices, treatment couches, surface guidance systems, lasers, dosimetry equipment, phantoms, radiation detectors, QA systems, fiducial markers and workflow accessories.

Although individual products have lower average selling prices than major treatment systems, demand is recurring and closely linked to equipment installations and advanced treatment techniques. As SRS, SBRT and adaptive therapy increase, precise positioning and independent QA become more valuable.

By Application

Prostate Cancer

Prostate cancer is one of the most commercially important applications for U.S. radiation oncology devices. Approximately 313,780 new U.S. prostate cancer cases were estimated for 2025, supporting substantial use of IMRT, VMAT, SBRT, brachytherapy and proton therapy.

The segment is moving toward shorter-course radiation, precise image guidance and stereotactic treatment. Device differentiation therefore depends increasingly on prostate localization, treatment speed, organ-at-risk management and adaptive capability.

Breast Cancer

Breast cancer represents another major radiation treatment population, with approximately 316,950 invasive female breast cancer cases expected in 2025. Radiation is frequently used following breast-conserving surgery and in selected post-mastectomy cases.

Hypofractionation has materially changed breast radiation economics by reducing the number of visits required for many patients. Growth opportunities are strongest in image guidance, surface-guided radiation therapy, deep-inspiration breath hold and technologies that reduce cardiac and lung exposure.

Lung Cancer

Lung and bronchus cancer remains one of the leading cancer burdens in the United States. Approximately 226,650 new cases were estimated in 2025. Radiation devices are used across definitive chemoradiation, SBRT for early-stage disease, palliation and treatment of metastatic lesions.

Motion management is especially important because tumors can move with respiration. SBRT, respiratory gating, real-time tracking and high-quality treatment-room imaging are therefore important purchasing considerations for lung cancer programs.

Brain and Central Nervous System Tumors

Brain and CNS radiation treatment requires exceptional geometric accuracy because targets are often adjacent to neurologically critical structures. The application supports demand for SRS, fractionated stereotactic radiotherapy, high-definition multileaf collimation, intracranial immobilization, image guidance and specialized brachytherapy technologies.

Technology demand is also influenced by metastatic brain disease. Improvements in systemic cancer therapy have increased survival for many patients, creating greater use of focal intracranial radiation and repeat treatment.

Head and Neck Cancer

Head and neck cancer remains an important application for IMRT, VMAT, adaptive therapy and proton treatment. Complex anatomy and treatment-related changes in tumor volume or patient weight make this area particularly attractive for online adaptation.

Hospitals evaluating adaptive systems frequently view head and neck cancer as a key clinical use case because daily anatomical changes can affect both target coverage and dose to salivary glands, spinal cord and other structures.

Gynecologic, Gastrointestinal, Pediatric and Other Cancers

The remaining application pool includes cervical, uterine, rectal, pancreatic, liver, esophageal, pediatric, lymphoma, sarcoma and metastatic disease. Gynecologic oncology sustains demand for HDR brachytherapy, while liver and pancreatic disease support SBRT and motion-management technologies.

Pediatric oncology represents a strategically important proton therapy application because reducing radiation exposure to developing healthy tissue can have long-term value. Palliative treatment of bone and other metastases also represents substantial treatment volume and is increasingly suitable for shorter fractionation schedules.

By End User

Hospitals and Integrated Health Systems

Hospitals and health systems account for the largest share of U.S. radiation oncology device expenditure. These organizations operate substantial installed accelerator fleets and frequently purchase simulation equipment, planning platforms, QA technology and service contracts alongside treatment systems.

Large integrated delivery networks increasingly negotiate enterprise agreements and standardize radiation technology across multiple facilities. Vendor selection depends on clinical capability, interoperability, uptime guarantees, training support and long-term service economics.

Academic and Comprehensive Cancer Centers

Academic and NCI-designated cancer centers are strategically important because they adopt advanced technologies early, conduct clinical research and influence treatment standards. Adaptive radiotherapy, proton treatment, novel stereotactic platforms and biology-guided radiation often achieve initial penetration in these institutions.

These providers may tolerate greater workflow complexity when a technology provides meaningful clinical differentiation or research value, making them critical reference sites for emerging manufacturers.

Freestanding Radiation Therapy Centers

Freestanding centers represent an important but financially pressured segment. These facilities frequently serve community populations and can provide radiation treatment closer to patients than large tertiary centers.

Their capital decisions are particularly sensitive to reimbursement, staffing and treatment-room utilization. Equipment with smaller infrastructure requirements, high uptime and streamlined workflow can therefore have disproportionate appeal.

Proton and Particle Therapy Centers

Dedicated proton facilities form a specialized end-user segment with unique requirements for particle accelerators, gantries, beam delivery, imaging, treatment planning, dosimetry and maintenance.

The U.S. proton footprint has expanded to approximately 50 operating centers, while additional locations remain in development. Future procurement will increasingly involve upgrades, additional rooms and replacement of early-generation infrastructure in addition to greenfield centers.

Community Oncology Networks and Regional Cancer Centers

Regional cancer networks serve a large proportion of U.S. oncology patients and represent an important growth segment for advanced but operationally efficient radiation systems. These organizations must balance clinical sophistication with staffing constraints and reimbursement exposure.

High-throughput linacs, cloud-connected planning, centralized dosimetry, remote physics support, surface guidance and automated QA can help these networks extend advanced treatment into smaller markets.

By Technology Type

Image-Guided Radiation Therapy

IGRT is foundational to modern radiation oncology because high-quality imaging allows clinicians to confirm patient anatomy and target position near treatment time. CBCT, kV imaging and other on-board imaging technologies are increasingly integrated into accelerator purchasing decisions.

Advanced IGRT is also the foundation for adaptive therapy, making imaging quality a central competitive variable.

Intensity-Modulated and Volumetric Arc Therapy

IMRT and VMAT remain core technologies across prostate, head and neck, brain, lung and other disease sites. These techniques allow radiation dose to conform more closely to the target while limiting exposure to surrounding organs.

The market is mature, but replacement demand remains strong as providers seek faster dose delivery, improved multileaf collimators and more automated planning.

Stereotactic Radiosurgery and SBRT

SRS and SBRT represent high-value technology categories because they deliver highly focused radiation in a limited number of fractions. Adoption continues across brain, lung, spine, prostate, liver and oligometastatic disease.

The technology requires strong imaging, immobilization, motion management, QA and treatment accuracy, creating secondary demand across multiple device categories.

Adaptive Radiotherapy

Adaptive radiotherapy is expected to be among the fastest-growing technology categories through 2035. CT-Linac, advanced CBCT-guided and MR-guided systems can use current patient anatomy to determine whether the original plan remains optimal.

Commercial success will depend on reducing adaptive-session duration and minimizing the specialist workload required for replanning.

Motion Management and Surface-Guided Radiation Therapy

Surface-guided radiation therapy and real-time motion-management systems are becoming important workflow components, especially for breast, lung, liver and stereotactic treatment.

These systems support markerless patient positioning, respiratory monitoring and automated beam interruption when motion exceeds predefined tolerances. Their value increases as treatment margins become smaller.

Proton and Advanced Particle Beam Delivery

Proton beam delivery uses the physical properties of charged particles to reduce exit dose beyond the tumor. The technology continues to attract major academic and regional investment despite high capital requirements.

The next phase of the market will focus on compact systems, improved image guidance, faster delivery, adaptive proton planning and potential U.S. commercialization of carbon-ion treatment.

Regional Insights: Where the Market is Growing Fastest

The U.S. Radiation Oncology Devices Market is geographically segmented into the South, West, Northeast and Midwest. Regional performance differs based on cancer incidence, population age, hospital concentration, academic oncology infrastructure, payer mix, proton therapy availability, rural access and health-system capital investment.

The South is the largest market, while the West is expected to record the fastest growth through 2035. The Northeast remains the most academically concentrated high-acuity market, while the Midwest provides a large and stable installed base with significant replacement demand.

South

The South represented an estimated USD 1.25 billion in 2025 and is expected to approach USD 2.99 billion by 2035, reflecting approximately 9.1% annual growth.

Regional leadership is supported by population growth, large cancer incidence, expanding hospital systems and high concentrations of older adults in states such as Florida. The region also has substantial underserved and rural territory, creating simultaneous opportunities for advanced tertiary-center equipment and scalable community radiation infrastructure.

Florida recorded approximately 171,960 expected new cancer cases in 2025, while Texas accounted for approximately 150,870. North Carolina recorded roughly 71,320, Georgia approximately 66,210, Virginia about 50,510, Tennessee approximately 42,750 and Maryland around 37,200.

Florida is becoming particularly important for advanced radiation infrastructure. Its older population supports high volumes of prostate, breast, lung and metastatic cancer treatment, while proton therapy capacity continues expanding across Jacksonville, Miami, Orlando, South Florida and other markets. Development of particle therapy infrastructure in Florida, including carbon-ion ambitions, could make the state one of the most strategically important U.S. advanced radiation markets during the forecast period.

Texas remains a major radiation oncology purchasing market because of its combination of population scale and large tertiary medical centers in Houston, Dallas-Fort Worth, Austin and San Antonio. Houston is especially influential because of its globally recognized cancer-care ecosystem and established proton infrastructure.

North Carolina, Georgia, Tennessee and South Carolina are emerging as important health-system investment markets. Population growth and consolidation among regional health systems support replacement of older LINACs with advanced platforms. A notable example is the USD 50 million radiation-therapy-related technology and services investment announced between Siemens Healthineers and Prisma Health, covering operations in South Carolina and Tennessee.

Rural access is a major strategic issue in Mississippi, Alabama, Arkansas, Louisiana, Kentucky, Oklahoma and West Virginia. Equipment vendors that can support single-machine facilities, remote workflow, centralized planning and reliable maintenance can address a different need from manufacturers targeting comprehensive urban cancer centers.

West

The West represented approximately USD 0.84 billion in 2025 and is projected to reach roughly USD 2.18 billion by 2035, making it the fastest-growing U.S. region at approximately 10.0% CAGR.

California is the primary market, with approximately 199,980 expected new cancer cases in 2025, the highest state total in the country. Washington recorded approximately 46,500 cases, Arizona 42,560, Colorado 29,020, Oregon 26,980, Utah 14,120 and Nevada 17,540.

California combines large treatment volume with an unusually strong medical-technology ecosystem. Major academic institutions and integrated delivery networks are early adopters of stereotactic, adaptive and biology-guided radiation systems. The state also contains important radiation oncology manufacturers and technology innovators, increasing interaction between device development and clinical adoption.

Arizona is a strong market for radiation equipment because of demographic growth, retirement migration and major cancer programs. Proton therapy infrastructure and large integrated systems provide attractive opportunities for high-value treatment technologies.

Washington, Oregon, Colorado and Utah have sophisticated health systems with strong adoption of digital and image-guided treatment. Utah’s proton capability also serves patients from surrounding Mountain West states, illustrating the regional-referral economics associated with advanced radiation equipment.

Nevada, Idaho, Montana, Wyoming, Alaska and parts of New Mexico remain characterized by substantial travel requirements for highly specialized radiation therapy. Over the forecast period, compact high-throughput treatment platforms, remote planning and regional satellite centers could improve access without requiring every market to build a tertiary cancer center.

Northeast

The Northeast represented approximately USD 0.88 billion in 2025 and is expected to reach approximately USD 1.94 billion by 2035, expanding at around 8.2% CAGR.

New York accounted for approximately 123,430 expected new cancer cases in 2025, Pennsylvania about 90,240, New Jersey approximately 59,840, Massachusetts 44,000, Connecticut 23,920, New Hampshire 10,290, Maine 11,080, Rhode Island 7,480, Delaware 7,680 and Vermont approximately 4,670.

New York is the region’s largest market and combines dense treatment volume with large academic and multi-hospital oncology systems. The state is an important environment for advanced radiosurgery, adaptive radiotherapy, image guidance and proton treatment.

Massachusetts has a disproportionate influence on technology adoption because of its research institutions and academic cancer programs. Boston remains a major market for complex radiation oncology, proton therapy, treatment planning research and evidence generation.

Pennsylvania is particularly important because of its large cancer volume and advanced radiation infrastructure around Philadelphia, Pittsburgh and regional health systems. The state has an established proton therapy presence and a sophisticated academic oncology ecosystem.

New Jersey and Connecticut benefit from dense population and close integration with New York and Philadelphia referral markets. The Northeast overall is likely to grow more slowly than the West because of mature installed infrastructure and slower population expansion, but average technology intensity per facility is likely to remain high.

Midwest

The Midwest represented approximately USD 0.65 billion in 2025 and is expected to reach about USD 1.34 billion by 2035, reflecting approximately 7.5% CAGR.

Illinois accounted for approximately 78,870 estimated new cancer cases in 2025, Ohio approximately 77,010, Michigan 66,040, Indiana 42,150, Wisconsin 39,940, Missouri 39,220, Minnesota 37,650, Iowa 21,340, Kansas 15,810 and Nebraska 12,390.

Illinois remains the region’s largest market because of Chicago’s academic and community oncology infrastructure. The state also has established proton therapy capacity and newer particle therapy investment outside Chicago.

Ohio has a large cancer burden and extensive academic and regional cancer infrastructure across Cleveland, Columbus and Cincinnati. Expansion of proton capacity has strengthened its importance for particle therapy vendors.

Michigan maintains significant radiation-treatment demand across large hospital systems and community cancer programs. Minnesota is commercially influential because of its medical-device ecosystem and major academic institutions, while proton infrastructure strengthens its high-end treatment market.

Wisconsin is emerging as another advanced-technology market with new proton capabilities. Indiana, Missouri, Iowa, Kansas and Nebraska provide substantial demand for conventional LINAC replacement, stereotactic treatment systems, image guidance and QA technology.

The Midwest’s strategic challenge is geographic dispersion. Rural areas can be located considerable distances from high-acuity cancer centers. Manufacturers able to combine reliable equipment, centralized planning, remote support and efficient staffing models can create strong value propositions in these markets.

Key Market Players

The U.S. Radiation Oncology Devices Competitive Landscape is highly concentrated in major external-beam treatment delivery platforms but considerably more fragmented across particle therapy, brachytherapy, planning, positioning, QA and treatment accessories.

Varian, a Siemens Healthineers company, and Elekta represent the two largest integrated conventional radiotherapy platform competitors. Accuray maintains a differentiated position through CyberKnife and Radixact technologies, while RefleXion is developing a distinct biology-guided treatment architecture.

Particle therapy competition includes IBA, Mevion and Hitachi. Treatment planning, positioning, imaging and QA create additional competitive layers involving RaySearch, Brainlab, GE HealthCare, Vision RT, C-RAD, Mirion/Sun Nuclear and other specialized manufacturers.

Some of the key players operating in or supplying the U.S. Radiation Oncology Devices Market include:

Siemens Healthineers / Varian
Elekta
Accuray Incorporated
IBA
Mevion Medical Systems
Hitachi
RefleXion Medical
Brainlab
RaySearch Laboratories
GE HealthCare
Philips
Canon Medical Systems USA
Mirion Technologies / Sun Nuclear
Vision RT
C-RAD
LAP
CQ Medical
Best Medical International
Eckert & Ziegler BEBIG
Theragenics Corporation
IsoAid
GT Medical Technologies
Becton, Dickinson and Company
Bionix Radiation Therapy

Competitive advantage during 2026–2035 will depend increasingly on ecosystem depth. Accelerator vendors must demonstrate imaging quality, adaptive capability, planning integration, uptime, cybersecurity, service responsiveness and cost per treatment. Proton vendors will compete around footprint, throughput, beam performance and total facility economics.

Smaller specialized manufacturers can remain strategically important because precision radiation depends on multiple components outside the treatment machine. Surface guidance, immobilization, dosimetry, QA, brachytherapy and motion-management companies can capture recurring revenue even when accelerator installations remain concentrated among a few major vendors.

Recent Developments

The U.S. radiation oncology equipment market entered 2026 with one of its most significant technology refresh cycles in several years.

In January 2026, Elekta received U.S. FDA 510(k) clearance for the Elekta Evo CT-Linac. The platform incorporates advanced CT imaging and AI-enhanced visualization designed to support conventional and adaptive radiotherapy. U.S. clearance creates a new competitive alternative as hospitals evaluate next-generation adaptive platforms.

Varian also continues expanding the capabilities of its Ethos and Halcyon systems. U.S. regulatory activity covering newer versions of these platforms during 2026 strengthens Varian’s adaptive and high-throughput portfolio. Its broader strategy increasingly links treatment systems with HyperSight imaging, Eclipse planning, ARIA oncology management and Siemens Healthineers diagnostic imaging.

In late 2025, the FDA cleared the RefleXion X2 next-generation platform. The company announced the clearance in January 2026, positioning X2 as an advanced external-beam oncology platform capable of supporting its SCINTIX biology-guided treatment approach for selected tumors.

Health-system capital commitments also demonstrate continued appetite for premium radiation technology. In July 2025, Prisma Health and Siemens Healthineers announced an expanded partnership involving approximately USD 50 million in radiation therapy technology and services investment, including Varian Ethos adaptive radiotherapy.

The U.S. proton therapy landscape continues to expand. Approximately 50 proton centers were operating nationally by 2026, with additional sites and expansions under development. Single-room technology is broadening the economics of proton deployment, while planned carbon-ion capabilities represent a potential next frontier for particle therapy.

At the same time, reimbursement has emerged as one of the most important market risks. Radiation oncology practices reported significant financial pressure following 2026 Medicare coding and payment changes. The effect is especially important for freestanding and rural facilities, where capital expenditure flexibility is lower.

This reimbursement pressure is expected to accelerate consolidation and technology selectivity. Hospitals may delay low-priority replacements while protecting investment in systems that deliver measurable workflow benefits, support premium clinical programs or consolidate several treatment capabilities onto one platform.

Conclusion

The U.S. Radiation Oncology Devices Market Size & Share is projected to expand from approximately USD 3.62 billion in 2025 to USD 8.44 billion by 2035, at a CAGR of 8.83% during 2026–2035.

The long-term market opportunity is supported by a combination of more than two million annual U.S. cancer diagnoses, widespread use of radiation during cancer treatment, continued replacement of the installed LINAC base, expansion of stereotactic treatment, development of adaptive radiotherapy, increasing proton capacity and growing demand for automation.

External-beam systems will remain the largest product category, but value creation will increasingly migrate toward platforms that combine treatment delivery with advanced imaging, planning intelligence, adaptive workflow and motion management. Proton therapy and biology-guided radiation represent high-value emerging areas, while patient positioning, surface guidance, QA and dosimetry will benefit from increasing precision requirements.

From a clinical economics perspective, the defining market metric during the forecast period will be productive treatment capacity. Hospitals will favor technologies that enable more clinically appropriate treatments per room, reduce staffing burden, shorten setup and imaging, support hypofractionation and maintain predictable uptime.

Regional growth will remain uneven. The South will retain the largest share because of population scale, cancer burden and health-system expansion. The West is expected to grow fastest because of technology adoption, population shifts and a strong innovation ecosystem. The Northeast will remain a premium academic market, while the Midwest will provide substantial accelerator replacement and regional access opportunities.

California, Florida, Texas and New York will remain the most commercially significant individual state markets because they collectively represented approximately 646,000 expected new cancer cases in 2025. Pennsylvania, Illinois, Ohio, North Carolina, Georgia, Michigan, New Jersey, Virginia, Washington, Massachusetts and Arizona will also remain strategically important device markets.

The largest commercial risk is not lack of clinical demand but affordability of infrastructure. Medicare reimbursement pressure, staffing shortages and rural-site closures can constrain capital investment even as the underlying cancer population grows. Vendors able to deliver advanced capabilities at sustainable operating economics will therefore be better positioned than manufacturers competing solely on technological complexity.

For hospitals, medtech manufacturers, investors and oncology networks evaluating this market, the central strategic questions will be which adaptive technologies become routine, how rapidly hypofractionation changes treatment-room economics, whether proton therapy continues migrating toward smaller facilities, how reimbursement reforms influence freestanding centers, and which manufacturers can build truly integrated radiation oncology ecosystems.

The next decade of the U.S. radiation oncology devices industry will be defined by precision without operational complexity. Technologies that improve tumor targeting while reducing treatment time, planning burden, staff dependency and total cost per episode are likely to capture the strongest share of future capital expenditure.

TABLE OF CONTENT

1. U.S. Radiation Oncology Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Market Sizing, Triangulation & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Radiation Oncology Device Manufacturers
1.6.2. Radiation Source, Component and Contract Manufacturing Suppliers
1.6.3. Hospitals and Integrated Health Systems
1.6.4. Academic and Comprehensive Cancer Centers
1.6.5. Freestanding Radiation Therapy Centers
1.6.6. Proton and Particle Therapy Centers
1.6.7. Medical Physicists, Dosimetrists and Radiation Oncology Professionals
1.6.8. Group Purchasing Organizations, Distributors and Service Providers
1.6.9. Payers, Regulators and Clinical Decision-Makers

What this section provides: This section establishes the definition, market boundaries, research methodology, assumptions and stakeholder ecosystem used to measure and validate the U.S. radiation oncology devices market.

2. U.S. Radiation Oncology Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. Market Size Outlook, 2025–2035 (US$ Billion)
2.8. High-Growth Opportunity Areas
2.9. Major Radiation Oncology Capital Investment Themes
2.10. Key Clinical and Technology Adoption Indicators

What this section provides: This section gives decision-makers a concise view of market size, historical performance, forecast growth, technology adoption, capital spending priorities and the most attractive opportunity areas through 2035.

3. U.S. Radiation Oncology Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising U.S. Cancer Incidence and Treatment Demand
3.1.2. Growing Adoption of Hypofractionation and Precision Radiotherapy
3.1.3. Replacement and Modernization of Installed Linear Accelerators
3.1.4. Expansion of SRS and SBRT Procedures
3.1.5. Growth of Adaptive Radiation Therapy
3.1.6. Expansion of Proton and Particle Therapy Infrastructure
3.1.7. Growing Demand for Image-Guided Radiation Therapy
3.1.8. Radiation Oncology Workforce Constraints Driving Automation
3.2. Restraints and Their Impact Analysis
3.2.1. High Capital Cost of Advanced Radiation Therapy Systems
3.2.2. Medicare Reimbursement and Payment Pressure
3.2.3. High Facility Construction and Shielding Requirements
3.2.4. Long Replacement Cycles for Installed Radiation Equipment
3.2.5. Medical Physics and Radiation Therapist Workforce Shortages
3.3. Opportunities and Their Impact Analysis
3.3.1. CT-Guided Adaptive Radiotherapy
3.3.2. AI-Assisted Treatment Planning and Auto-Contouring
3.3.3. Surface-Guided Radiation Therapy
3.3.4. Compact and Single-Room Proton Therapy Systems
3.3.5. Biology-Guided Radiation Therapy
3.3.6. Cloud-Based Radiation Oncology Workflow
3.3.7. Rural and Community Radiation Oncology Infrastructure Expansion
3.4. Challenges and Their Impact Analysis
3.4.1. Treatment Workflow Complexity
3.4.2. Capital Budget Competition Within Hospital Systems
3.4.3. Technology Integration and Interoperability
3.4.4. Radiation Safety, QA and Regulatory Compliance
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Workflow Economics Analysis
3.7. Radiation Treatment Room Throughput Analysis
3.8. Hospital Capital Procurement Behavior Analysis
3.9. Installed Base Replacement Cycle Analysis
3.10. Reimbursement Sensitivity Analysis

What this section provides: This section evaluates the clinical, technological, reimbursement, capital procurement and operational forces influencing radiation oncology equipment demand and identifies both growth opportunities and execution risks.

4. U.S. Radiation Oncology Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Radiation Oncology Equipment Pricing Trend Analysis, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Radiation Oncology Capital Equipment Lifecycle Analysis
4.6. Application & Innovation Landscape
4.7. FDA Medical Device Regulatory Framework Analysis
4.8. Radiation-Producing Equipment Regulatory Framework
4.9. CMS Reimbursement and Coverage Landscape
4.10. Radiation Oncology Coding and Payment Dynamics
4.11. Import/Export Restrictions & Tariff Impact
4.12. Government Cancer Care Initiatives
4.13. Radiation Safety and Quality Assurance Requirements
4.14. Cybersecurity and Software Interoperability Requirements
4.15. Impact of AI and Automation on Radiation Oncology
4.16. Impact of Escalating Geopolitical and Supply Chain Tensions
4.17. Hospital Value Analysis Committee Decision Framework
4.18. Total Cost of Ownership Analysis for Radiation Oncology Platforms

What this section provides: This section gives clients a comprehensive assessment of the regulatory, reimbursement, technology, pricing, supply-chain, safety and procurement environment affecting U.S. radiation oncology device commercialization.

5. U.S. Radiation Oncology Devices Market – By Product Category

5.1. Overview
5.1.1. Segment Share Analysis, By Product Category, 2025 & 2035 (%)
5.1.2. External Beam Radiation Therapy Systems
5.1.2.1. Medical Linear Accelerators
5.1.2.2. Conventional LINAC Systems
5.1.2.3. CT-Linac Systems
5.1.2.4. MR-Guided Radiation Therapy Systems
5.1.2.5. Robotic Radiosurgery Systems
5.1.2.6. Helical Radiation Therapy Systems
5.1.2.7. Dedicated Stereotactic Radiosurgery Systems
5.1.3. Brachytherapy Devices
5.1.3.1. High-Dose-Rate Afterloaders
5.1.3.2. Low-Dose-Rate Brachytherapy Systems
5.1.3.3. Brachytherapy Applicators
5.1.3.4. Brachytherapy Needles and Catheters
5.1.3.5. Electronic Brachytherapy Systems
5.1.3.6. Implantable Radiation Delivery Devices
5.1.4. Particle Therapy Systems
5.1.4.1. Proton Beam Therapy Systems
5.1.4.2. Multi-Room Proton Therapy Systems
5.1.4.3. Single-Room Proton Therapy Systems
5.1.4.4. Pencil Beam Scanning Systems
5.1.4.5. Carbon-Ion and Advanced Particle Therapy Systems
5.1.5. Simulation and Imaging Systems
5.1.5.1. CT Simulation Systems
5.1.5.2. MRI Simulation Systems
5.1.5.3. Cone-Beam CT Systems
5.1.5.4. Treatment-Room Imaging Systems
5.1.5.5. Image Registration and Guidance Systems
5.1.6. Radiation Therapy Accessories, QA and Positioning Devices
5.1.6.1. Patient Immobilization Systems
5.1.6.2. Treatment Couches and Positioning Platforms
5.1.6.3. Surface Guidance Systems
5.1.6.4. Dosimetry and Radiation Measurement Equipment
5.1.6.5. Radiation Therapy QA Systems
5.1.6.6. Phantoms and Calibration Devices
5.1.6.7. Fiducial Markers and Localization Devices
5.1.6.8. Room Lasers and Alignment Systems

What this section provides: This section identifies the radiation oncology equipment categories generating the largest revenue pools and evaluates where LINAC modernization, particle therapy, brachytherapy, simulation, positioning and QA technologies will create growth through 2035.

6. U.S. Radiation Oncology Devices Market – By Application

6.1. Overview
6.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)
6.1.2. Prostate Cancer
6.1.2.1. External Beam Radiation Therapy
6.1.2.2. SBRT
6.1.2.3. Brachytherapy
6.1.2.4. Proton Therapy
6.1.3. Breast Cancer
6.1.3.1. Whole Breast Irradiation
6.1.3.2. Partial Breast Irradiation
6.1.3.3. Hypofractionated Radiation Therapy
6.1.3.4. Surface-Guided and Breath-Hold Radiation Therapy
6.1.4. Lung Cancer
6.1.4.1. Conventional Radiation Therapy
6.1.4.2. SBRT
6.1.4.3. Motion-Managed Radiation Therapy
6.1.4.4. Image-Guided Radiation Therapy
6.1.5. Brain and Central Nervous System Tumors
6.1.5.1. Stereotactic Radiosurgery
6.1.5.2. Fractionated Stereotactic Radiotherapy
6.1.5.3. Whole-Brain Radiation Therapy
6.1.5.4. Intracranial Brachytherapy
6.1.6. Head and Neck Cancer
6.1.6.1. IMRT
6.1.6.2. VMAT
6.1.6.3. Adaptive Radiotherapy
6.1.6.4. Proton Therapy
6.1.7. Gynecologic Cancer
6.1.7.1. External Beam Radiation Therapy
6.1.7.2. HDR Brachytherapy
6.1.7.3. Image-Guided Brachytherapy
6.1.8. Gastrointestinal and Hepatobiliary Cancer
6.1.8.1. Liver Cancer
6.1.8.2. Pancreatic Cancer
6.1.8.3. Rectal Cancer
6.1.8.4. Esophageal Cancer
6.1.9. Pediatric Cancer
6.1.10. Metastatic Cancer
6.1.11. Other Cancer Applications

What this section provides: This section evaluates radiation oncology equipment demand by cancer indication and identifies clinical applications where stereotactic treatment, adaptive therapy, proton therapy, brachytherapy and image guidance are creating the strongest device requirements.

7. U.S. Radiation Oncology Devices Market – By End User

7.1. Overview
7.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
7.1.2. Hospitals and Integrated Health Systems
7.1.2.1. Large Integrated Delivery Networks
7.1.2.2. Regional Hospital Systems
7.1.2.3. Community Hospitals
7.1.3. Academic and Comprehensive Cancer Centers
7.1.3.1. NCI-Designated Cancer Centers
7.1.3.2. University-Affiliated Cancer Centers
7.1.3.3. Research-Intensive Oncology Centers
7.1.4. Freestanding Radiation Therapy Centers
7.1.4.1. Physician-Owned Radiation Centers
7.1.4.2. Independent Community Radiation Centers
7.1.4.3. Multi-Site Radiation Oncology Networks
7.1.5. Proton and Particle Therapy Centers
7.1.5.1. Hospital-Affiliated Proton Centers
7.1.5.2. Academic Proton Therapy Centers
7.1.5.3. Independent Proton Therapy Facilities
7.1.6. Community Oncology Networks and Regional Cancer Centers
7.1.6.1. Multidisciplinary Community Cancer Centers
7.1.6.2. Rural and Regional Radiation Oncology Facilities
7.1.6.3. Satellite Radiation Therapy Centers

What this section provides: This section explains radiation oncology device purchasing behavior by facility type and highlights differences in capital budgets, technology adoption, treatment volumes, staffing economics and equipment replacement cycles.

8. U.S. Radiation Oncology Devices Market – By Technology Type

8.1. Overview
8.1.1. Segment Share Analysis, By Technology Type, 2025 & 2035 (%)
8.1.2. Image-Guided Radiation Therapy
8.1.2.1. Cone-Beam CT-Guided Radiation Therapy
8.1.2.2. kV/MV Image Guidance
8.1.2.3. MRI-Guided Radiation Therapy
8.1.2.4. Fiducial-Based Image Guidance
8.1.3. Intensity-Modulated and Volumetric Arc Therapy
8.1.3.1. IMRT
8.1.3.2. VMAT
8.1.3.3. High-Definition MLC-Based Treatment
8.1.4. Stereotactic Radiosurgery and SBRT
8.1.4.1. Intracranial SRS
8.1.4.2. Extracranial SBRT
8.1.4.3. Robotic Stereotactic Radiation Therapy
8.1.4.4. Frameless Radiosurgery
8.1.5. Adaptive Radiotherapy
8.1.5.1. CT-Guided Adaptive Radiotherapy
8.1.5.2. MR-Guided Adaptive Radiotherapy
8.1.5.3. CBCT-Based Adaptive Radiotherapy
8.1.5.4. AI-Assisted Online Adaptation
8.1.6. Motion Management and Surface-Guided Radiation Therapy
8.1.6.1. Surface-Guided Radiation Therapy
8.1.6.2. Respiratory Gating
8.1.6.3. Tumor Tracking
8.1.6.4. Deep-Inspiration Breath Hold
8.1.6.5. Real-Time Motion Monitoring
8.1.7. Proton and Advanced Particle Beam Delivery
8.1.7.1. Passive Scattering
8.1.7.2. Pencil Beam Scanning
8.1.7.3. Intensity-Modulated Proton Therapy
8.1.7.4. Carbon-Ion Therapy
8.1.7.5. Emerging FLASH and Ultra-High-Dose-Rate Platforms

What this section provides: This section evaluates the treatment technologies reshaping U.S. radiation oncology, including IGRT, IMRT, VMAT, stereotactic treatment, adaptive radiotherapy, motion management, proton therapy and emerging advanced beam-delivery technologies.

9. U.S. Radiation Oncology Devices Market – By Geography

9.1. Introduction
9.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
9.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
9.1.3. Regional Cancer Incidence and Radiation Treatment Demand Analysis
9.1.4. Regional Radiation Oncology Facility Density Analysis
9.1.5. Regional LINAC Installed Base and Replacement Opportunity
9.1.6. Regional Proton and Particle Therapy Infrastructure Analysis
9.1.7. Regional Reimbursement and Capital Procurement Dynamics
9.2. West Region
9.2.1. Regional Overview & Trends
9.2.2. West Region Radiation Oncology Device Manufacturers and Procurement Ecosystem
9.2.3. West Region Cancer Incidence and Radiation Therapy Capacity
9.2.4. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.2.5. West Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.6. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.7. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.8. West Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.2.9. California
9.2.9.1. Overview
9.2.9.2. California Market Size and Forecast, By Product Category, 2021–2035
9.2.9.3. California Market Size and Forecast, By Application, 2021–2035
9.2.9.4. California Market Size and Forecast, By End User, 2021–2035
9.2.9.5. California Market Size and Forecast, By Technology Type, 2021–2035
9.2.10. Washington
9.2.10.1. Overview
9.2.10.2. Washington Market Size and Forecast, By Product Category, 2021–2035
9.2.10.3. Washington Market Size and Forecast, By Application, 2021–2035
9.2.10.4. Washington Market Size and Forecast, By End User, 2021–2035
9.2.10.5. Washington Market Size and Forecast, By Technology Type, 2021–2035
9.2.11. Arizona
9.2.11.1. Overview
9.2.11.2. Arizona Market Size and Forecast, By Product Category, 2021–2035
9.2.11.3. Arizona Market Size and Forecast, By Application, 2021–2035
9.2.11.4. Arizona Market Size and Forecast, By End User, 2021–2035
9.2.11.5. Arizona Market Size and Forecast, By Technology Type, 2021–2035
9.2.12. Colorado
9.2.12.1. Overview
9.2.12.2. Colorado Market Size and Forecast, By Product Category, 2021–2035
9.2.12.3. Colorado Market Size and Forecast, By Application, 2021–2035
9.2.12.4. Colorado Market Size and Forecast, By End User, 2021–2035
9.2.12.5. Colorado Market Size and Forecast, By Technology Type, 2021–2035
9.2.13. Oregon
9.2.13.1. Overview
9.2.13.2. Oregon Market Size and Forecast, By Product Category, 2021–2035
9.2.13.3. Oregon Market Size and Forecast, By Application, 2021–2035
9.2.13.4. Oregon Market Size and Forecast, By End User, 2021–2035
9.2.13.5. Oregon Market Size and Forecast, By Technology Type, 2021–2035
9.2.14. Utah
9.2.14.1. Overview
9.2.14.2. Utah Market Size and Forecast, By Product Category, 2021–2035
9.2.14.3. Utah Market Size and Forecast, By Application, 2021–2035
9.2.14.4. Utah Market Size and Forecast, By End User, 2021–2035
9.2.14.5. Utah Market Size and Forecast, By Technology Type, 2021–2035
9.2.15. Nevada
9.2.15.1. Overview
9.2.15.2. Nevada Market Size and Forecast, By Product Category, 2021–2035
9.2.15.3. Nevada Market Size and Forecast, By Application, 2021–2035
9.2.15.4. Nevada Market Size and Forecast, By End User, 2021–2035
9.2.15.5. Nevada Market Size and Forecast, By Technology Type, 2021–2035
9.2.16. New Mexico
9.2.16.1. Overview
9.2.16.2. New Mexico Market Size and Forecast, By Product Category, 2021–2035
9.2.16.3. New Mexico Market Size and Forecast, By Application, 2021–2035
9.2.16.4. New Mexico Market Size and Forecast, By End User, 2021–2035
9.2.16.5. New Mexico Market Size and Forecast, By Technology Type, 2021–2035
9.2.17. Idaho
9.2.17.1. Overview
9.2.17.2. Idaho Market Size and Forecast, By Product Category, 2021–2035
9.2.17.3. Idaho Market Size and Forecast, By Application, 2021–2035
9.2.17.4. Idaho Market Size and Forecast, By End User, 2021–2035
9.2.17.5. Idaho Market Size and Forecast, By Technology Type, 2021–2035
9.2.18. Montana
9.2.18.1. Overview
9.2.18.2. Montana Market Size and Forecast, By Product Category, 2021–2035
9.2.18.3. Montana Market Size and Forecast, By Application, 2021–2035
9.2.18.4. Montana Market Size and Forecast, By End User, 2021–2035
9.2.18.5. Montana Market Size and Forecast, By Technology Type, 2021–2035
9.2.19. Wyoming
9.2.19.1. Overview
9.2.19.2. Wyoming Market Size and Forecast, By Product Category, 2021–2035
9.2.19.3. Wyoming Market Size and Forecast, By Application, 2021–2035
9.2.19.4. Wyoming Market Size and Forecast, By End User, 2021–2035
9.2.19.5. Wyoming Market Size and Forecast, By Technology Type, 2021–2035
9.2.20. Alaska
9.2.20.1. Overview
9.2.20.2. Alaska Market Size and Forecast, By Product Category, 2021–2035
9.2.20.3. Alaska Market Size and Forecast, By Application, 2021–2035
9.2.20.4. Alaska Market Size and Forecast, By End User, 2021–2035
9.2.20.5. Alaska Market Size and Forecast, By Technology Type, 2021–2035
9.2.21. Hawaii
9.2.21.1. Overview
9.2.21.2. Hawaii Market Size and Forecast, By Product Category, 2021–2035
9.2.21.3. Hawaii Market Size and Forecast, By Application, 2021–2035
9.2.21.4. Hawaii Market Size and Forecast, By End User, 2021–2035
9.2.21.5. Hawaii Market Size and Forecast, By Technology Type, 2021–2035
9.3. Northeast Region
9.3.1. Regional Overview & Trends
9.3.2. Northeast Region Radiation Oncology Device Manufacturers and Procurement Ecosystem
9.3.3. Northeast Region Cancer Incidence and Radiation Therapy Capacity
9.3.4. Northeast Region Market Size and Forecast, By State, 2021–2035
9.3.5. Northeast Region Market Size and Forecast, By Product Category, 2021–2035
9.3.6. Northeast Region Market Size and Forecast, By Application, 2021–2035
9.3.7. Northeast Region Market Size and Forecast, By End User, 2021–2035
9.3.8. Northeast Region Market Size and Forecast, By Technology Type, 2021–2035
9.3.9. New York
9.3.9.1. Overview
9.3.9.2. New York Market Size and Forecast, By Product Category, 2021–2035
9.3.9.3. New York Market Size and Forecast, By Application, 2021–2035
9.3.9.4. New York Market Size and Forecast, By End User, 2021–2035
9.3.9.5. New York Market Size and Forecast, By Technology Type, 2021–2035
9.3.10. Massachusetts
9.3.10.1. Overview
9.3.10.2. Massachusetts Market Size and Forecast, By Product Category, 2021–2035
9.3.10.3. Massachusetts Market Size and Forecast, By Application, 2021–2035
9.3.10.4. Massachusetts Market Size and Forecast, By End User, 2021–2035
9.3.10.5. Massachusetts Market Size and Forecast, By Technology Type, 2021–2035
9.3.11. New Jersey
9.3.11.1. Overview
9.3.11.2. New Jersey Market Size and Forecast, By Product Category, 2021–2035
9.3.11.3. New Jersey Market Size and Forecast, By Application, 2021–2035
9.3.11.4. New Jersey Market Size and Forecast, By End User, 2021–2035
9.3.11.5. New Jersey Market Size and Forecast, By Technology Type, 2021–2035
9.3.12. Pennsylvania
9.3.12.1. Overview
9.3.12.2. Pennsylvania Market Size and Forecast, By Product Category, 2021–2035
9.3.12.3. Pennsylvania Market Size and Forecast, By Application, 2021–2035
9.3.12.4. Pennsylvania Market Size and Forecast, By End User, 2021–2035
9.3.12.5. Pennsylvania Market Size and Forecast, By Technology Type, 2021–2035
9.3.13. Connecticut
9.3.13.1. Overview
9.3.13.2. Connecticut Market Size and Forecast, By Product Category, 2021–2035
9.3.13.3. Connecticut Market Size and Forecast, By Application, 2021–2035
9.3.13.4. Connecticut Market Size and Forecast, By End User, 2021–2035
9.3.13.5. Connecticut Market Size and Forecast, By Technology Type, 2021–2035
9.3.14. Maine
9.3.14.1. Overview
9.3.14.2. Maine Market Size and Forecast, By Product Category, 2021–2035
9.3.14.3. Maine Market Size and Forecast, By Application, 2021–2035
9.3.14.4. Maine Market Size and Forecast, By End User, 2021–2035
9.3.14.5. Maine Market Size and Forecast, By Technology Type, 2021–2035
9.3.15. Vermont
9.3.15.1. Overview
9.3.15.2. Vermont Market Size and Forecast, By Product Category, 2021–2035
9.3.15.3. Vermont Market Size and Forecast, By Application, 2021–2035
9.3.15.4. Vermont Market Size and Forecast, By End User, 2021–2035
9.3.15.5. Vermont Market Size and Forecast, By Technology Type, 2021–2035
9.3.16. New Hampshire
9.3.16.1. Overview
9.3.16.2. New Hampshire Market Size and Forecast, By Product Category, 2021–2035
9.3.16.3. New Hampshire Market Size and Forecast, By Application, 2021–2035
9.3.16.4. New Hampshire Market Size and Forecast, By End User, 2021–2035
9.3.16.5. New Hampshire Market Size and Forecast, By Technology Type, 2021–2035
9.3.17. Rhode Island
9.3.17.1. Overview
9.3.17.2. Rhode Island Market Size and Forecast, By Product Category, 2021–2035
9.3.17.3. Rhode Island Market Size and Forecast, By Application, 2021–2035
9.3.17.4. Rhode Island Market Size and Forecast, By End User, 2021–2035
9.3.17.5. Rhode Island Market Size and Forecast, By Technology Type, 2021–2035
9.3.18. Delaware
9.3.18.1. Overview
9.3.18.2. Delaware Market Size and Forecast, By Product Category, 2021–2035
9.3.18.3. Delaware Market Size and Forecast, By Application, 2021–2035
9.3.18.4. Delaware Market Size and Forecast, By End User, 2021–2035
9.3.18.5. Delaware Market Size and Forecast, By Technology Type, 2021–2035
9.4. South Region
9.4.1. Regional Overview & Trends
9.4.2. South Region Radiation Oncology Device Manufacturers and Procurement Ecosystem
9.4.3. South Region Cancer Incidence and Radiation Therapy Capacity
9.4.4. South Region Market Size and Forecast, By State, 2021–2035
9.4.5. South Region Market Size and Forecast, By Product Category, 2021–2035
9.4.6. South Region Market Size and Forecast, By Application, 2021–2035
9.4.7. South Region Market Size and Forecast, By End User, 2021–2035
9.4.8. South Region Market Size and Forecast, By Technology Type, 2021–2035
9.4.9. Texas
9.4.9.1. Overview
9.4.9.2. Texas Market Size and Forecast, By Product Category, 2021–2035
9.4.9.3. Texas Market Size and Forecast, By Application, 2021–2035
9.4.9.4. Texas Market Size and Forecast, By End User, 2021–2035
9.4.9.5. Texas Market Size and Forecast, By Technology Type, 2021–2035
9.4.10. Florida
9.4.10.1. Overview
9.4.10.2. Florida Market Size and Forecast, By Product Category, 2021–2035
9.4.10.3. Florida Market Size and Forecast, By Application, 2021–2035
9.4.10.4. Florida Market Size and Forecast, By End User, 2021–2035
9.4.10.5. Florida Market Size and Forecast, By Technology Type, 2021–2035
9.4.11. Georgia
9.4.11.1. Overview
9.4.11.2. Georgia Market Size and Forecast, By Product Category, 2021–2035
9.4.11.3. Georgia Market Size and Forecast, By Application, 2021–2035
9.4.11.4. Georgia Market Size and Forecast, By End User, 2021–2035
9.4.11.5. Georgia Market Size and Forecast, By Technology Type, 2021–2035
9.4.12. North Carolina
9.4.12.1. Overview
9.4.12.2. North Carolina Market Size and Forecast, By Product Category, 2021–2035
9.4.12.3. North Carolina Market Size and Forecast, By Application, 2021–2035
9.4.12.4. North Carolina Market Size and Forecast, By End User, 2021–2035
9.4.12.5. North Carolina Market Size and Forecast, By Technology Type, 2021–2035
9.4.13. Tennessee
9.4.13.1. Overview
9.4.13.2. Tennessee Market Size and Forecast, By Product Category, 2021–2035
9.4.13.3. Tennessee Market Size and Forecast, By Application, 2021–2035
9.4.13.4. Tennessee Market Size and Forecast, By End User, 2021–2035
9.4.13.5. Tennessee Market Size and Forecast, By Technology Type, 2021–2035
9.4.14. South Carolina
9.4.14.1. Overview
9.4.14.2. South Carolina Market Size and Forecast, By Product Category, 2021–2035
9.4.14.3. South Carolina Market Size and Forecast, By Application, 2021–2035
9.4.14.4. South Carolina Market Size and Forecast, By End User, 2021–2035
9.4.14.5. South Carolina Market Size and Forecast, By Technology Type, 2021–2035
9.4.15. Alabama
9.4.15.1. Overview
9.4.15.2. Alabama Market Size and Forecast, By Product Category, 2021–2035
9.4.15.3. Alabama Market Size and Forecast, By Application, 2021–2035
9.4.15.4. Alabama Market Size and Forecast, By End User, 2021–2035
9.4.15.5. Alabama Market Size and Forecast, By Technology Type, 2021–2035
9.4.16. Mississippi
9.4.16.1. Overview
9.4.16.2. Mississippi Market Size and Forecast, By Product Category, 2021–2035
9.4.16.3. Mississippi Market Size and Forecast, By Application, 2021–2035
9.4.16.4. Mississippi Market Size and Forecast, By End User, 2021–2035
9.4.16.5. Mississippi Market Size and Forecast, By Technology Type, 2021–2035
9.4.17. Louisiana
9.4.17.1. Overview
9.4.17.2. Louisiana Market Size and Forecast, By Product Category, 2021–2035
9.4.17.3. Louisiana Market Size and Forecast, By Application, 2021–2035
9.4.17.4. Louisiana Market Size and Forecast, By End User, 2021–2035
9.4.17.5. Louisiana Market Size and Forecast, By Technology Type, 2021–2035
9.4.18. Arkansas
9.4.18.1. Overview
9.4.18.2. Arkansas Market Size and Forecast, By Product Category, 2021–2035
9.4.18.3. Arkansas Market Size and Forecast, By Application, 2021–2035
9.4.18.4. Arkansas Market Size and Forecast, By End User, 2021–2035
9.4.18.5. Arkansas Market Size and Forecast, By Technology Type, 2021–2035
9.4.19. Kentucky
9.4.19.1. Overview
9.4.19.2. Kentucky Market Size and Forecast, By Product Category, 2021–2035
9.4.19.3. Kentucky Market Size and Forecast, By Application, 2021–2035
9.4.19.4. Kentucky Market Size and Forecast, By End User, 2021–2035
9.4.19.5. Kentucky Market Size and Forecast, By Technology Type, 2021–2035
9.4.20. Oklahoma
9.4.20.1. Overview
9.4.20.2. Oklahoma Market Size and Forecast, By Product Category, 2021–2035
9.4.20.3. Oklahoma Market Size and Forecast, By Application, 2021–2035
9.4.20.4. Oklahoma Market Size and Forecast, By End User, 2021–2035
9.4.20.5. Oklahoma Market Size and Forecast, By Technology Type, 2021–2035
9.4.21. Virginia
9.4.21.1. Overview
9.4.21.2. Virginia Market Size and Forecast, By Product Category, 2021–2035
9.4.21.3. Virginia Market Size and Forecast, By Application, 2021–2035
9.4.21.4. Virginia Market Size and Forecast, By End User, 2021–2035
9.4.21.5. Virginia Market Size and Forecast, By Technology Type, 2021–2035
9.4.22. Maryland
9.4.22.1. Overview
9.4.22.2. Maryland Market Size and Forecast, By Product Category, 2021–2035
9.4.22.3. Maryland Market Size and Forecast, By Application, 2021–2035
9.4.22.4. Maryland Market Size and Forecast, By End User, 2021–2035
9.4.22.5. Maryland Market Size and Forecast, By Technology Type, 2021–2035
9.4.23. West Virginia
9.4.23.1. Overview
9.4.23.2. West Virginia Market Size and Forecast, By Product Category, 2021–2035
9.4.23.3. West Virginia Market Size and Forecast, By Application, 2021–2035
9.4.23.4. West Virginia Market Size and Forecast, By End User, 2021–2035
9.4.23.5. West Virginia Market Size and Forecast, By Technology Type, 2021–2035
9.5. Midwest Region
9.5.1. Regional Overview & Trends
9.5.2. Midwest Region Radiation Oncology Device Manufacturers and Procurement Ecosystem
9.5.3. Midwest Region Cancer Incidence and Radiation Therapy Capacity
9.5.4. Midwest Region Market Size and Forecast, By State, 2021–2035
9.5.5. Midwest Region Market Size and Forecast, By Product Category, 2021–2035
9.5.6. Midwest Region Market Size and Forecast, By Application, 2021–2035
9.5.7. Midwest Region Market Size and Forecast, By End User, 2021–2035
9.5.8. Midwest Region Market Size and Forecast, By Technology Type, 2021–2035
9.5.9. Illinois
9.5.9.1. Overview
9.5.9.2. Illinois Market Size and Forecast, By Product Category, 2021–2035
9.5.9.3. Illinois Market Size and Forecast, By Application, 2021–2035
9.5.9.4. Illinois Market Size and Forecast, By End User, 2021–2035
9.5.9.5. Illinois Market Size and Forecast, By Technology Type, 2021–2035
9.5.10. Ohio
9.5.10.1. Overview
9.5.10.2. Ohio Market Size and Forecast, By Product Category, 2021–2035
9.5.10.3. Ohio Market Size and Forecast, By Application, 2021–2035
9.5.10.4. Ohio Market Size and Forecast, By End User, 2021–2035
9.5.10.5. Ohio Market Size and Forecast, By Technology Type, 2021–2035
9.5.11. Michigan
9.5.11.1. Overview
9.5.11.2. Michigan Market Size and Forecast, By Product Category, 2021–2035
9.5.11.3. Michigan Market Size and Forecast, By Application, 2021–2035
9.5.11.4. Michigan Market Size and Forecast, By End User, 2021–2035
9.5.11.5. Michigan Market Size and Forecast, By Technology Type, 2021–2035
9.5.12. Minnesota
9.5.12.1. Overview
9.5.12.2. Minnesota Market Size and Forecast, By Product Category, 2021–2035
9.5.12.3. Minnesota Market Size and Forecast, By Application, 2021–2035
9.5.12.4. Minnesota Market Size and Forecast, By End User, 2021–2035
9.5.12.5. Minnesota Market Size and Forecast, By Technology Type, 2021–2035
9.5.13. Indiana
9.5.13.1. Overview
9.5.13.2. Indiana Market Size and Forecast, By Product Category, 2021–2035
9.5.13.3. Indiana Market Size and Forecast, By Application, 2021–2035
9.5.13.4. Indiana Market Size and Forecast, By End User, 2021–2035
9.5.13.5. Indiana Market Size and Forecast, By Technology Type, 2021–2035
9.5.14. Wisconsin
9.5.14.1. Overview
9.5.14.2. Wisconsin Market Size and Forecast, By Product Category, 2021–2035
9.5.14.3. Wisconsin Market Size and Forecast, By Application, 2021–2035
9.5.14.4. Wisconsin Market Size and Forecast, By End User, 2021–2035
9.5.14.5. Wisconsin Market Size and Forecast, By Technology Type, 2021–2035
9.5.15. Missouri
9.5.15.1. Overview
9.5.15.2. Missouri Market Size and Forecast, By Product Category, 2021–2035
9.5.15.3. Missouri Market Size and Forecast, By Application, 2021–2035
9.5.15.4. Missouri Market Size and Forecast, By End User, 2021–2035
9.5.15.5. Missouri Market Size and Forecast, By Technology Type, 2021–2035
9.5.16. Iowa
9.5.16.1. Overview
9.5.16.2. Iowa Market Size and Forecast, By Product Category, 2021–2035
9.5.16.3. Iowa Market Size and Forecast, By Application, 2021–2035
9.5.16.4. Iowa Market Size and Forecast, By End User, 2021–2035
9.5.16.5. Iowa Market Size and Forecast, By Technology Type, 2021–2035
9.5.17. Kansas
9.5.17.1. Overview
9.5.17.2. Kansas Market Size and Forecast, By Product Category, 2021–2035
9.5.17.3. Kansas Market Size and Forecast, By Application, 2021–2035
9.5.17.4. Kansas Market Size and Forecast, By End User, 2021–2035
9.5.17.5. Kansas Market Size and Forecast, By Technology Type, 2021–2035
9.5.18. Nebraska
9.5.18.1. Overview
9.5.18.2. Nebraska Market Size and Forecast, By Product Category, 2021–2035
9.5.18.3. Nebraska Market Size and Forecast, By Application, 2021–2035
9.5.18.4. Nebraska Market Size and Forecast, By End User, 2021–2035
9.5.18.5. Nebraska Market Size and Forecast, By Technology Type, 2021–2035
9.5.19. North Dakota
9.5.19.1. Overview
9.5.19.2. North Dakota Market Size and Forecast, By Product Category, 2021–2035
9.5.19.3. North Dakota Market Size and Forecast, By Application, 2021–2035
9.5.19.4. North Dakota Market Size and Forecast, By End User, 2021–2035
9.5.19.5. North Dakota Market Size and Forecast, By Technology Type, 2021–2035
9.5.20. South Dakota
9.5.20.1. Overview
9.5.20.2. South Dakota Market Size and Forecast, By Product Category, 2021–2035
9.5.20.3. South Dakota Market Size and Forecast, By Application, 2021–2035
9.5.20.4. South Dakota Market Size and Forecast, By End User, 2021–2035
9.5.20.5. South Dakota Market Size and Forecast, By Technology Type, 2021–2035

What this section provides: This section delivers comprehensive regional and state-level intelligence, helping clients identify high-priority U.S. radiation oncology markets, cancer-treatment hubs, LINAC replacement opportunities, proton therapy clusters, technology-adoption hotspots and underserved geographic opportunities.

10. U.S. Radiation Oncology Devices Market: Competitive Landscape & Company Profiles

10.1. Market Share Analysis, 2025
10.2. Competitive Benchmarking
10.3. Company Positioning Matrix
10.3.1. Leaders
10.3.2. Challengers
10.3.3. Innovators
10.3.4. Emerging Players
10.4. Product Portfolio Comparison
10.5. Radiation Oncology Platform Ecosystem Comparison
10.6. Installed Base and U.S. Commercial Presence Analysis
10.7. Strategic Partnerships, M&A and Technology Alliances
10.8. Company Profiles
10.8.1. Siemens Healthineers / Varian
10.8.2. Elekta
10.8.3. Accuray Incorporated
10.8.4. IBA
10.8.5. Mevion Medical Systems
10.8.6. Hitachi
10.8.7. RefleXion Medical
10.8.8. Brainlab
10.8.9. RaySearch Laboratories
10.8.10. GE HealthCare
10.8.11. Philips
10.8.12. Canon Medical Systems USA
10.8.13. Mirion Technologies / Sun Nuclear
10.8.14. Vision RT
10.8.15. C-RAD
10.8.16. LAP
10.8.17. CQ Medical
10.8.18. Best Medical International
10.8.19. Eckert & Ziegler BEBIG
10.8.20. Theragenics Corporation
10.8.21. IsoAid
10.8.22. GT Medical Technologies
10.8.23. Becton, Dickinson and Company
10.8.24. Bionix Radiation Therapy
10.8.25. Standard Imaging
10.9. Company Profile Coverage Framework
10.9.1. Company Overview
10.9.2. Radiation Oncology Device Portfolio
10.9.3. U.S. Market Presence
10.9.4. Product and Technology Positioning
10.9.5. Financial and Strategic Positioning
10.9.6. Clinical and Product Pipeline
10.9.7. FDA Regulatory Updates
10.9.8. Partnerships and Collaborations
10.9.9. Recent Developments

What this section provides: This section provides competitor benchmarking, market-share visibility, portfolio comparisons, installed-base positioning, innovation strategies and detailed intelligence on leading U.S. radiation oncology device manufacturers and specialized technology suppliers.

11. U.S. Radiation Oncology Devices Market: Future Market Outlook, 2026–2035

11.1. Scenario Analysis
11.1.1. Optimistic Scenario
11.1.2. Realistic Scenario
11.1.3. Pessimistic Scenario
11.2. Disruptive Technologies Impact
11.2.1. Online Adaptive Radiotherapy
11.2.2. AI-Assisted Treatment Planning
11.2.3. Biology-Guided Radiation Therapy
11.2.4. Advanced CBCT and Treatment-Room Imaging
11.2.5. MR-Guided Radiation Therapy
11.2.6. Surface-Guided Radiation Therapy
11.2.7. Compact Proton Therapy
11.2.8. Carbon-Ion Therapy
11.2.9. FLASH and Ultra-High-Dose-Rate Radiation Therapy
11.2.10. Digital Twins and Automated Treatment Optimization
11.3. Future LINAC Replacement Opportunity
11.4. Future Proton Therapy Capacity Expansion
11.5. Future Radiation Oncology Workforce and Automation Outlook
11.6. Emerging Business Trends
11.7. Consolidation of Radiation Oncology Networks
11.8. Business Opportunities for Startups and Existing Players
11.9. Investment Prioritization Matrix
11.10. Technology Adoption Roadmap, 2026–2035

What this section provides: This section prepares clients for future technology shifts, treatment workflow evolution, installed-base replacement opportunities, particle therapy expansion, emerging business models and alternative market-growth scenarios through 2035.

12. U.S. Radiation Oncology Devices Market: Strategic Recommendations

12.1. Recommendations for Radiation Oncology Device Manufacturers
12.2. Recommendations for Hospitals and Integrated Health Systems
12.3. Recommendations for Academic and Comprehensive Cancer Centers
12.4. Recommendations for Community Radiation Oncology Providers
12.5. Recommendations for Proton and Particle Therapy Developers
12.6. Recommendations for Investors and Private Equity Firms
12.7. Recommendations for Distributors and Specialty Channel Partners
12.8. Recommendations for New Entrants and Startups
12.9. U.S. Go-to-Market Strategy Considerations
12.10. Hospital Capital Procurement Strategy
12.11. Product Positioning and Portfolio Expansion Guidance
12.12. Regional Market Prioritization Strategy
12.13. Reimbursement and Health-Economic Evidence Strategy
12.14. Partnership and Clinical Evidence Development Strategy
12.15. Service, Maintenance and Recurring Revenue Strategy

What this section provides: This section converts the market analysis into actionable recommendations for product strategy, capital equipment commercialization, regional expansion, investment decisions, reimbursement positioning and competitive differentiation.

13. U.S. Radiation Oncology Devices Market: Disclaimer

13.1. Scope Limitation
13.2. Market Definition Limitation
13.3. Data Use Limitation
13.4. Forecasting Limitation
13.5. State-Level Market Estimation Limitation
13.6. Regulatory and Reimbursement Data Limitation
13.7. Legal Disclaimer
13.8. Third-Party Data Disclaimer

What this section provides: This section clarifies the report’s scope, market-estimation boundaries, data-use terms, state-level modeling limitations, regulatory assumptions, forecasting methodology limitations and legal considerations.

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Radiation Oncology Devices Market: Market Definition and Scope
TABLE 3: U.S. Radiation Oncology Devices Market: Research Methodology Framework
TABLE 4: U.S. Radiation Oncology Devices Market: Market Sizing, Triangulation and Forecasting Framework
TABLE 5: U.S. Radiation Oncology Devices Market: Key Assumptions
TABLE 6: U.S. Radiation Oncology Devices Market: Stakeholder and Market Ecosystem Analysis
TABLE 7: U.S. Radiation Oncology Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Radiation Oncology Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Radiation Oncology Devices Market: Market Attractiveness Index
TABLE 10: U.S. Radiation Oncology Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Radiation Oncology Devices Market: Base Year Market Positioning, 2025
TABLE 12: U.S. Radiation Oncology Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 13: U.S. Radiation Oncology Devices Market: High-Growth Opportunity Areas, 2026–2035
TABLE 14: U.S. Radiation Oncology Devices Market: Drivers and Impact Analysis
TABLE 15: U.S. Radiation Oncology Devices Market: Restraints and Impact Analysis
TABLE 16: U.S. Radiation Oncology Devices Market: Opportunities and Impact Analysis
TABLE 17: U.S. Radiation Oncology Devices Market: Challenges and Impact Analysis
TABLE 18: U.S. Radiation Oncology Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 19: U.S. Radiation Oncology Devices Market: Clinical Workflow Economics Matrix
TABLE 20: U.S. Radiation Oncology Devices Market: Radiation Treatment Room Throughput Analysis
TABLE 21: U.S. Radiation Oncology Devices Market: Hospital Capital Procurement Behavior Matrix
TABLE 22: U.S. Radiation Oncology Devices Market: Installed Base Replacement and Reimbursement Sensitivity Analysis
TABLE 23: U.S. Radiation Oncology Devices Market: PESTEL Analysis
TABLE 24: U.S. Radiation Oncology Devices Market: Porter’s Five Forces Analysis
TABLE 25: U.S. Radiation Oncology Devices Market: Equipment Pricing Trend Analysis, 2025–2035
TABLE 26: U.S. Radiation Oncology Devices Market: Value Chain Analysis
TABLE 27: U.S. Radiation Oncology Devices Market: Supply Chain Analysis
TABLE 28: U.S. Radiation Oncology Devices Market: Capital Equipment Lifecycle Analysis
TABLE 29: U.S. Radiation Oncology Devices Market: Application & Innovation Landscape
TABLE 30: U.S. Radiation Oncology Devices Market: FDA Medical Device Regulatory Framework
TABLE 31: U.S. Radiation Oncology Devices Market: Radiation-Producing Equipment Regulatory Framework
TABLE 32: U.S. Radiation Oncology Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 33: U.S. Radiation Oncology Devices Market: Radiation Oncology Coding and Payment Dynamics
TABLE 34: U.S. Radiation Oncology Devices Market: Radiation Safety and Quality Assurance Requirements
TABLE 35: U.S. Radiation Oncology Devices Market: AI, Automation and Software Interoperability Impact
TABLE 36: U.S. Radiation Oncology Devices Market: Hospital Value Analysis Committee Decision Framework
TABLE 37: U.S. Radiation Oncology Devices Market: Total Cost of Ownership Framework
TABLE 38: U.S. Radiation Oncology Devices Market: Product Category Snapshot, 2025
TABLE 39: Segment Dashboard; Definition and Scope, by Product Category
TABLE 40: U.S. Radiation Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 41: U.S. Radiation Oncology Devices Market: Segment Share Analysis, by Product Category, 2025 & 2035 (%)
TABLE 42: External Beam Radiation Therapy Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 43: Brachytherapy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 44: Particle Therapy Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 45: Simulation and Imaging Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: Radiation Therapy Accessories, QA and Positioning Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: U.S. Radiation Oncology Devices Market: Application Snapshot, 2025
TABLE 48: Segment Dashboard; Definition and Scope, by Application
TABLE 49: U.S. Radiation Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 50: U.S. Radiation Oncology Devices Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 51: Prostate Cancer Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 52: Breast Cancer Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 53: Lung Cancer Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: Brain and Central Nervous System Tumors Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: Head and Neck Cancer Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 56: Gynecologic Cancer Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: Gastrointestinal and Hepatobiliary Cancer Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 58: Pediatric, Metastatic and Other Cancer Applications Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 59: U.S. Radiation Oncology Devices Market: End User Snapshot, 2025
TABLE 60: Segment Dashboard; Definition and Scope, by End User
TABLE 61: U.S. Radiation Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 62: U.S. Radiation Oncology Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 63: Hospitals and Integrated Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: Academic and Comprehensive Cancer Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 65: Freestanding Radiation Therapy Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: Proton, Particle Therapy and Community Cancer Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 67: U.S. Radiation Oncology Devices Market: Technology Type Snapshot, 2025
TABLE 68: Segment Dashboard; Definition and Scope, by Technology Type
TABLE 69: U.S. Radiation Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 70: U.S. Radiation Oncology Devices Market: Segment Share Analysis, by Technology Type, 2025 & 2035 (%)
TABLE 71: Image-Guided Radiation Therapy Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: IMRT and Volumetric Arc Therapy Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: Stereotactic Radiosurgery and SBRT Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 74: Adaptive Radiotherapy Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: Motion Management, Surface Guidance and Advanced Particle Beam Delivery Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 76: U.S. Radiation Oncology Devices Market: Regional Snapshot, 2025
TABLE 77: Segment Dashboard; Definition and Scope, by Geography
TABLE 78: U.S. Radiation Oncology Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 79: U.S. Radiation Oncology Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 80: West Region U.S. Radiation Oncology Devices Market: Regional Overview and Trends
TABLE 81: West Region: Cancer Incidence, Radiation Therapy Capacity and Procurement Ecosystem
TABLE 82: West Region U.S. Radiation Oncology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 83: West Region Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 84: West Region Market, by Application, 2021–2035 (US$ Billion)
TABLE 85: West Region Market, by End User and Technology Type, 2021–2035 (US$ Billion)
TABLE 86: California Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 87: Washington Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 88: Arizona Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 89: Colorado Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 90: Oregon Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 91: Utah Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 92: Nevada Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 93: New Mexico Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 94: Idaho Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 95: Montana Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 96: Wyoming Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 97: Alaska Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 98: Hawaii Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 99: Northeast Region U.S. Radiation Oncology Devices Market: Regional Overview and Trends
TABLE 100: Northeast Region: Cancer Incidence, Radiation Therapy Capacity and Procurement Ecosystem
TABLE 101: Northeast Region U.S. Radiation Oncology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 102: Northeast Region Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 103: Northeast Region Market, by Application, 2021–2035 (US$ Billion)
TABLE 104: Northeast Region Market, by End User and Technology Type, 2021–2035 (US$ Billion)
TABLE 105: New York Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 106: Massachusetts Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 107: New Jersey Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 108: Pennsylvania Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 109: Connecticut Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 110: Maine Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 111: Vermont Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 112: New Hampshire Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 113: Rhode Island Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 114: Delaware Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 115: South Region U.S. Radiation Oncology Devices Market: Regional Overview and Trends
TABLE 116: South Region: Cancer Incidence, Radiation Therapy Capacity and Procurement Ecosystem
TABLE 117: South Region U.S. Radiation Oncology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 118: South Region Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 119: South Region Market, by Application, 2021–2035 (US$ Billion)
TABLE 120: South Region Market, by End User and Technology Type, 2021–2035 (US$ Billion)
TABLE 121: Texas Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 122: Florida Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 123: Georgia Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 124: North Carolina Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 125: Tennessee Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 126: South Carolina Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 127: Alabama Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 128: Mississippi Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 129: Louisiana Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 130: Arkansas Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 131: Kentucky Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 132: Oklahoma Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 133: Virginia Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 134: Maryland Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 135: West Virginia Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 136: Midwest Region U.S. Radiation Oncology Devices Market: Regional Overview and Trends
TABLE 137: Midwest Region: Cancer Incidence, Radiation Therapy Capacity and Procurement Ecosystem
TABLE 138: Midwest Region U.S. Radiation Oncology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 139: Midwest Region Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 140: Midwest Region Market, by Application, 2021–2035 (US$ Billion)
TABLE 141: Midwest Region Market, by End User and Technology Type, 2021–2035 (US$ Billion)
TABLE 142: Illinois Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 143: Ohio Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 144: Michigan Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 145: Minnesota Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 146: Indiana Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 147: Wisconsin Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 148: Missouri Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 149: Iowa Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 150: Kansas Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 151: Nebraska Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 152: North Dakota Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 153: South Dakota Radiation Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 154: U.S. Radiation Oncology Devices Market: Competitive Landscape Snapshot, 2025
TABLE 155: U.S. Radiation Oncology Devices Market: Key Company Market Share Analysis, 2025
TABLE 156: U.S. Radiation Oncology Devices Market: Company Positioning Matrix
TABLE 157: U.S. Radiation Oncology Devices Market: Product Portfolio Benchmarking
TABLE 158: U.S. Radiation Oncology Devices Market: Radiation Oncology Platform Ecosystem Comparison
TABLE 159: U.S. Radiation Oncology Devices Market: Installed Base and U.S. Commercial Presence Analysis
TABLE 160: U.S. Radiation Oncology Devices Market: Strategic Developments, Partnerships and M&A
TABLE 161: Siemens Healthineers / Varian: Company Profile
TABLE 162: Elekta: Company Profile
TABLE 163: Accuray Incorporated: Company Profile
TABLE 164: IBA: Company Profile
TABLE 165: Mevion Medical Systems: Company Profile
TABLE 166: Hitachi: Company Profile
TABLE 167: RefleXion Medical: Company Profile
TABLE 168: Brainlab: Company Profile
TABLE 169: RaySearch Laboratories: Company Profile
TABLE 170: GE HealthCare: Company Profile
TABLE 171: Philips: Company Profile
TABLE 172: Canon Medical Systems USA: Company Profile
TABLE 173: Mirion Technologies / Sun Nuclear: Company Profile
TABLE 174: Vision RT: Company Profile
TABLE 175: C-RAD: Company Profile
TABLE 176: LAP: Company Profile
TABLE 177: CQ Medical: Company Profile
TABLE 178: Best Medical International: Company Profile
TABLE 179: Eckert & Ziegler BEBIG: Company Profile
TABLE 180: Theragenics Corporation: Company Profile
TABLE 181: IsoAid: Company Profile
TABLE 182: GT Medical Technologies: Company Profile
TABLE 183: Becton, Dickinson and Company: Company Profile
TABLE 184: Bionix Radiation Therapy: Company Profile
TABLE 185: Standard Imaging: Company Profile
TABLE 186: U.S. Radiation Oncology Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 187: U.S. Radiation Oncology Devices Market: Disruptive Technologies Impact Matrix
TABLE 188: U.S. Radiation Oncology Devices Market: Adaptive Radiotherapy Adoption Outlook
TABLE 189: U.S. Radiation Oncology Devices Market: LINAC Replacement Opportunity, 2026–2035
TABLE 190: U.S. Radiation Oncology Devices Market: Proton Therapy Capacity Expansion Outlook
TABLE 191: U.S. Radiation Oncology Devices Market: AI and Automation Adoption Outlook
TABLE 192: U.S. Radiation Oncology Devices Market: Emerging Business Trends
TABLE 193: U.S. Radiation Oncology Devices Market: Business Opportunities for Startups and Existing Players
TABLE 194: U.S. Radiation Oncology Devices Market: Investment Prioritization Matrix
TABLE 195: U.S. Radiation Oncology Devices Market: Strategic Recommendations for Device Manufacturers
TABLE 196: U.S. Radiation Oncology Devices Market: Strategic Recommendations for Hospitals and Health Systems
TABLE 197: U.S. Radiation Oncology Devices Market: Strategic Recommendations for Academic Cancer Centers
TABLE 198: U.S. Radiation Oncology Devices Market: Strategic Recommendations for Community Radiation Providers
TABLE 199: U.S. Radiation Oncology Devices Market: Strategic Recommendations for Proton Therapy Developers
TABLE 200: U.S. Radiation Oncology Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 201: U.S. Radiation Oncology Devices Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 202: U.S. Radiation Oncology Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 203: U.S. Radiation Oncology Devices Market: Go-to-Market Strategy Considerations
TABLE 204: U.S. Radiation Oncology Devices Market: Regional Market Prioritization Framework
TABLE 205: U.S. Radiation Oncology Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 206: U.S. Radiation Oncology Devices Market: Scope Limitation
TABLE 207: U.S. Radiation Oncology Devices Market: Market Definition Limitation
TABLE 208: U.S. Radiation Oncology Devices Market: Data Use Limitation
TABLE 209: U.S. Radiation Oncology Devices Market: Forecasting Limitation
TABLE 210: U.S. Radiation Oncology Devices Market: State-Level Market Estimation Limitation
TABLE 211: U.S. Radiation Oncology Devices Market: Regulatory and Reimbursement Data Limitation
TABLE 212: U.S. Radiation Oncology Devices Market: Legal Disclaimer
TABLE 213: U.S. Radiation Oncology Devices Market: Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. Radiation Oncology Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Market Sizing and Data Triangulation Framework
FIGURE 4: Radiation Oncology Device Market Ecosystem
FIGURE 5: Market Attractiveness Analysis
FIGURE 6: U.S. Radiation Oncology Devices Market Dynamics
FIGURE 7: Innovation & Patent Landscape, 2021–2025
FIGURE 8: Radiation Oncology Clinical Workflow Economics Framework
FIGURE 9: Radiation Treatment Room Throughput Framework
FIGURE 10: Hospital Capital Procurement Decision Framework
FIGURE 11: PESTEL Analysis
FIGURE 12: Porter’s Five Forces Analysis
FIGURE 13: Value Chain and Supply Chain Analysis
FIGURE 14: U.S. Radiation Oncology Devices Market Size, Historical and Forecast Trend, 2021–2035 (US$ Billion)
FIGURE 15: Product Category Segment Market Share Analysis, 2025 & 2035
FIGURE 16: Product Category Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 17: External Beam Radiation Therapy Systems Market Forecast, 2021–2035 (US$ Billion)
FIGURE 18: Brachytherapy Devices Market Forecast, 2021–2035 (US$ Billion)
FIGURE 19: Particle Therapy Systems Market Forecast, 2021–2035 (US$ Billion)
FIGURE 20: Simulation and Imaging Systems Market Forecast, 2021–2035 (US$ Billion)
FIGURE 21: Radiation Therapy Accessories, QA and Positioning Devices Market Forecast, 2021–2035 (US$ Billion)
FIGURE 22: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 23: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 24: Prostate Cancer Radiation Oncology Devices Market Forecast, 2021–2035
FIGURE 25: Breast Cancer Radiation Oncology Devices Market Forecast, 2021–2035
FIGURE 26: Lung Cancer Radiation Oncology Devices Market Forecast, 2021–2035
FIGURE 27: Brain and CNS Tumor Radiation Oncology Devices Market Forecast, 2021–2035
FIGURE 28: Head and Neck Cancer Radiation Oncology Devices Market Forecast, 2021–2035
FIGURE 29: Gynecologic Cancer Radiation Oncology Devices Market Forecast, 2021–2035
FIGURE 30: Gastrointestinal and Hepatobiliary Cancer Devices Market Forecast, 2021–2035
FIGURE 31: Pediatric, Metastatic and Other Cancer Applications Market Forecast, 2021–2035
FIGURE 32: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 33: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Hospitals and Integrated Health Systems Market Forecast, 2021–2035
FIGURE 35: Academic and Comprehensive Cancer Centers Market Forecast, 2021–2035
FIGURE 36: Freestanding Radiation Therapy Centers Market Forecast, 2021–2035
FIGURE 37: Proton, Particle Therapy and Community Cancer Centers Market Forecast, 2021–2035
FIGURE 38: Technology Type Segment Market Share Analysis, 2025 & 2035
FIGURE 39: Technology Type Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: Image-Guided Radiation Therapy Market Forecast, 2021–2035
FIGURE 41: IMRT and VMAT Market Forecast, 2021–2035
FIGURE 42: Stereotactic Radiosurgery and SBRT Market Forecast, 2021–2035
FIGURE 43: Adaptive Radiotherapy Market Forecast, 2021–2035
FIGURE 44: Motion Management, Surface Guidance and Advanced Particle Therapy Outlook
FIGURE 45: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 46: Regional Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 47: West Region Market Share Analysis by State, 2025
FIGURE 48: California Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 49: Washington Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 50: Arizona Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 51: Colorado Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 52: Oregon Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 53: Utah Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 54: Nevada Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 55: New Mexico Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 56: Idaho Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 57: Montana Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 58: Wyoming Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 59: Alaska Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 60: Hawaii Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 61: Northeast Region Market Share Analysis by State, 2025
FIGURE 62: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: New York Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 64: Massachusetts Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 65: New Jersey Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 66: Pennsylvania Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 67: Connecticut Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 68: Maine Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 69: Vermont Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 70: New Hampshire Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 71: Rhode Island Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 72: Delaware Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 73: South Region Market Share Analysis by State, 2025
FIGURE 74: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: Texas Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 76: Florida Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 77: Georgia Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 78: North Carolina Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 79: Tennessee Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 80: South Carolina Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 81: Alabama Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 82: Mississippi Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 83: Louisiana Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 84: Arkansas Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 85: Kentucky Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 86: Oklahoma Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 87: Virginia Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 88: Maryland Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 89: West Virginia Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 90: Midwest Region Market Share Analysis by State, 2025
FIGURE 91: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: Illinois Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 93: Ohio Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 94: Michigan Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 95: Minnesota Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 96: Indiana Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 97: Wisconsin Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 98: Missouri Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 99: Iowa Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 100: Kansas Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 101: Nebraska Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 102: North Dakota Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 103: South Dakota Radiation Oncology Devices Market Size and Forecast, 2021–2035
FIGURE 104: Competitive Landscape and Key Company Market Share Analysis, 2025
FIGURE 105: Radiation Oncology Device Company Positioning Matrix
FIGURE 106: Key Player Product Portfolio Benchmarking
FIGURE 107: Radiation Oncology Platform Ecosystem Comparison
FIGURE 108: U.S. Installed Base and Commercial Presence Map
FIGURE 109: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 110: Radiation Oncology Device Innovation Roadmap
FIGURE 111: Future Market Scenario Analysis, 2026–2035
FIGURE 112: Disruptive Technologies Impact Matrix
FIGURE 113: Adaptive Radiotherapy Adoption Roadmap
FIGURE 114: U.S. LINAC Replacement Opportunity Roadmap, 2026–2035
FIGURE 115: Proton and Particle Therapy Capacity Expansion Roadmap
FIGURE 116: AI-Assisted Treatment Planning and Automation Roadmap
FIGURE 117: Biology-Guided Radiation Therapy Opportunity Map
FIGURE 118: Surface-Guided and Motion Management Technology Roadmap
FIGURE 119: Emerging Radiation Oncology Business Trends Matrix
FIGURE 120: Investment Prioritization Matrix
FIGURE 121: Technology Adoption Roadmap, 2026–2035
FIGURE 122: Strategic Growth Roadmap for Radiation Oncology Device Manufacturers
FIGURE 123: Hospital and Cancer Center Capital Procurement Strategy Framework
FIGURE 124: U.S. Go-to-Market Strategy Framework
FIGURE 125: Regional Market Prioritization Framework
FIGURE 126: Product Positioning and Portfolio Expansion Framework
FIGURE 127: Report Scope, Data Limitations and Disclaimer Framework